Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

CHAPTER

The Constellation Sales Process

There's a lot of interest in the space from larger pharmaceutical companies because there's unmet need. I mean, people really recognize that Jackified is great. But if it only works for 40% of patients to help their symptoms score and help their spleen volume, that's 60% of patients out there that aren't having disease control. It's kind of like, when I think of a drug, I'm like, Oh, yeah, it works for 85% of patients. Like it's crazy that there's a first line that's only 40%.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner